Oxytocin Antagonist for Repeated Implantationfailure and Delay of Delivery  by Liang, Yu-Ling et al.
Taiwan J Obstet Gynecol • September 2009 • Vol 48 • No 3
■ RESEARCH LETTER ■
314
Arginine vasopressin V1 receptors are present on human
myometrial specimens obtained at cesarean section
from women at the end of pregnancy (from 32 weeks to
term). Oxytocin receptors increase in human parturition
and are significantly correlated with the frequency of
uterine contractions [1]. Oxytocin and vasopressin 
receptors may play a role in the regulation of labor,
although increased oxytocin release primarily initiates
labor contractions. The mixed V1 arginine vasopressin
and oxytocin receptor antagonist, atosiban, is uterine-
specific, decreasing uterine contractions in pregnant
women, and is indicated for tocolysis in imminent pre-
mature birth [2]. Atosiban was developed specifically to
treat preterm labor and is widely used in many countries.
A single bolus of atosiban is indicated for acute tocolysis
in term labor, such as in fetal distress, and arrest of con-
tractions prior to emergency cesarean section. Atosiban
has little effect on maternal and fetal heart beats com-
pared with the significant effects of ritodrine, but appears
to have an immediate and profound effect on uterine
activity, comparable to that of ritodrine [3]. However,
a Cochrane review suggested that atosiban shows no
difference from placebo or other tocolytics in preventing
preterm labor or improving infant outcome [4]. Maternal
drug reactions with atosiban are increased compared
with placebo, but these side effects are reduced when
compared with beta-mimetics. Herein, we report a
couple with recurrent implantation failure (RIF) who
finally conceived successfully after an in vitro fertiliza-
tion (IVF)–embryo transfer (ET) cycle in which atosiban
was administered intravenously during embryo trans-
fer, and delivery of the second and third triplet was
delayed with the aid of atosiban infusion which inhibits
contractility in both the nonpregnant and pregnant
uterus.
This study was approved by the institutional review
board of National Cheng Kung University Hospital. We
report a 31-year-old patient, who experienced repeated
failure of IVF-ET, and underwent a seventh course of
controlled ovarian hyperstimulation. Informed consent
was obtained from the patient. At the first visit, a male
factor in infertility was suspected because of oligosper-
mia (semen analysis revealed sperm concentration of
7 × 105/mL and 57% motile sperm at grade 3 + 4). No
endocrine or genital structural abnormality was identi-
fied before infertility treatment. The couple had experi-
enced two courses of intrauterine insemination failure,
then four courses of IVF-ET with gonadotropin-releasing
hormone agonist or antagonist during gonadotropin
stimulation, and one course of frozen ET with good
embryo grading, but without success.
From counseling and in-depth interview, interper-
sonal stress (especially the marital factor) as a result of
the RIF was possibly the main reason for lack of success.
In the seventh controlled ovarian hyperstimulation cycle,
the patient was given a short gonadotropin-releasing
hormone agonist protocol which began with daily
buserelin nasal spray (Supremon; Hoechst, Frankfurt,
Germany) from day 2 of the menstrual cycle, and
recombinant gonadotropin (Gonal-F; Serono, Bari,
Italy) was administered from day 3 for 8 days with
1,500 IU in total. When two follicles reached 18 mm,
250 μg of recombinant human chorionic gonadotropin
(Ovitrelle; Serono) was injected, and transvaginal oocyte
retrieval was performed 34 hours later with 14 oocytes
collected, of which eight were fertilized normally. Three
embryos with good embryo grading (all four-cell grade 1)
were placed into the uterine cavity under transabdom-
inal ultrasound guiding with fully distended bladder
on day 2 after fertilization while two of the remaining
embryos were stored for cryopreservation. After coun-
seling for the anxiety related to ET, the patient received
atosiban (Tractocile; Ferring AB, Limhamn, Sweden)
infusion to reduce uterine activity with a bolus dose of
6.75 mg followed by infusion at 18 mg/hr for 3 hours
immediately after ET, resulting in a successful triplet
pregnancy.
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The pregnancy continued smoothly with regular
prenatal examinations. However, premature preterm
rupture of the membranes associated with uterine
contraction and cervical dilatation was found at a 
gestational age of 29 weeks, and a premature male
baby (the first triplet) was delivered vaginally as labor
progressed after intravenous ritodrine administration.
Successful tocolysis was achieved by atosiban infusion
(6.75 mg initial dose, 300 μg/min loading dose for 
3 hours, 100μg/min maintenance dose for 48–96 hours)
after delivery of the first triplet, whose umbilical cord
was clamped and packed back into vagina. The tocoly-
sis was continued until the patient could not tolerate
the persistent discomfort of full cervical dilation, and
two premature babies (the second and third triplet)
were delivered vaginally 7 days later.
Unfortunately, early postpartum hemorrhage and
transient low blood pressure were noted after extru-
sion of the three placentae but improved after uterine
massage and vaginal gauze packing. Late postpartum
hemorrhage occurred 1 week after delivery, and ultra-
sound revealed an intrauterine mass. Pathologic inves-
tigation confirmed retained placental tissue after the
procedure of dilation and curettage. The follow-up
period was subsequently uneventful.
Pierzynski et al [5] first reported that atosiban
reduced intense spontaneous uterine contractility as
visualized by transvaginal sonography, allowing improved
uterine receptivity resulting in successful embryo implan-
tation during ET after endometrial synchronization
with the donated oocyte recipient. We presented a
woman who was first treated with atosiban for RIF and
successfully conceived, then delivery of her second and
third triplet in preterm labor was delayed with the 
aid of atosiban infusion. Thus, atosiban inhibited con-
tractility in both the nonpregnant and pregnant uterus.
Good correlations between oxytocin receptor con-
centrations and uterine contractility have been observed
in both the pregnant and nonpregnant states [6].
Therefore, atosiban, a selective oxytocin receptor anta-
gonist capable of inhibiting uterine contractility, has
been proposed for clinical evaluation in dysmenorrhea
and preterm labor. It has been found to be compara-
ble in clinical tocolytic effectiveness to conventional 
β-agonist therapy, but with less maternal side effects
in preterm labor patients with intact membranes [7].
In this report, it was reasonably effective in the inhibition
of oxytocin-induced contractions of the myometrium
after delivery of the first baby of the triplet, allowing
the delayed delivery of the two remaining fetuses which
had intact membranes. Delayed delivery is recommended
in some cases of multiple pregnancy after the first
delivery, especially if this occurs early. Delayed delivery
of the remaining fetus(es) under 30 weeks’ gestation for
2 or more days, with careful observation of the fetal and
maternal condition, improves survival and decreases
morbidity among latter-born siblings [8]. The tocolytic
effect of atosiban helped to prevent delivery of the
remaining fetuses contemporaneously which improved
infant survival.
In spite of a high pregnancy rate following IVF-ET,
some couples, as in our case, have repeated failure of
ET after reasonably good embryos have been trans-
ferred. Further investigation should be initiated, such
as into psychologic factors. It is stressful during the
course of infertility treatment, especially when women
are undergoing IVF-ET. The emotional distress in infer-
tile women is often underestimated. More than 40% 
of infertile women who visited for a new course of
assisted reproductive technology treatment had a psy-
chiatric disorder, including anxiety and/or depression
[9]. This high prevalence of psychiatric morbidities 
is not affected by demographic features (including
age, education level, income, or years of infertility), or
a history of previous assisted conception treatment.
The negative impact of the psychologic factors may
contribute to implantation failure which reduces IVF
success. However, the effect of psychologic treatments
for infertile individuals lacks proof of efficacy in improv-
ing pregnancy rate [10].
As psychologic stressors are associated with preterm
labor [11], the elevated uterine contractile activity
(component of uterine receptivity) may also be related
to the increase in stress or anxiety during ET. Atosiban
may increase the success rates of infertility treatment
with the possibility that a reduction in stress responses
may help to increase uterine receptivity during ET,
especially in women with RIF. A significant decrease in
uterine contractility activity visualized by transvaginal
sonography was found after 1 hour of intravenous infu-
sion of atosiban [5]. Although we did not use ultrasonog-
raphy, a biologically plausible explanation for the benefit
of atosiban during ET in our case may be a decrease in
the uterine contractile activity induced by psychologic
stressors, resulting in successful embryo implantation
and a normal triplet pregnancy. However, it is equally
plausible that the patient may have conceived if she
had received no treatment at all. Further prospective
well-designed, randomized, controlled trials are needed
to compare atosiban with placebo infusion during ET in
women with RIF, after appropriate institutional review
board approval and informed consent.
The possible embryo toxicity of atosiban during
implantation in IVF-ET programs may be of concern.
The gene expressions of oxytocin and its receptor are
detected in human cumulus cells surrounding the
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oocytes [12]. The effect of oxytocin may enhance blas-
tocyst formation and play a physiologic role on embryo-
genesis in fertilized mouse oocytes. The messenger RNA
expressions of oxytocin receptor have been demonstrated
in mouse oocytes and embryos up to the blastocyst
stage [13]. Its expression is increased immediately after
fertilization which is compatible with a possible role of
oxytocin in this process, then oxytocin receptor messen-
ger RNA gradually decreases after the four-cell stage 
of pre-embryonic development. The expression of the
oxytocin receptor has also been shown in the mouse
uterus, suggesting that oxytocin may play a potential
role in the implantation process [13]. It is possible that
any drug utilized in IVF-ET programs, which involves
the interaction with the oxytocin receptor, will affect
the receptivity/quality of the implanting endometrium.
However, clinical application of atosiban is considered
for the novel indication of improvement of uterine
receptivity in ET recipients from an in vitro animal study
[14]. Preimplantation rabbit embryo development is
not affected by atosiban in concentrations 50-fold
higher than the mean plasma concentration reached
during regular therapy. A clinical case report [5] and
this case supported this hypothesis.
In conclusion, we suggest that the use of oxytocin
antagonist may be of benefit for IVF with RIF and for
delaying delivery in a multi-fetal pregnancy after IVF as
in this present report. The potential use of atosiban
will inhibit uterine contractility, which may be a good
intervention to help minimize the psychologic burdens
in women undergoing IVF, in the 2-week waiting period
prior to the pregnancy test. However, further random-
ized, controlled trials are required to investigate the
indication of oxytocin antagonist for ET in infertility
treatment, especially in cases of anxiety with RIF.
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